JPMorgan raised the firm’s price target on Ascendis Pharma (ASND) to $167 from $165 and keeps an Overweight rating on the shares. The analyst says Ascendis shares are down 6% year-to-date ...

JPMorgan upgraded Ciena (CIEN) to Overweight from Neutral with a price target of $88, up from $84. Concerns driven by the revelations around the capital efficiency of DeepSeek’s artificial ...

JPMorgan Chase on Wednesday posted record quarterly and annual earnings and revenue, reinforcing the company’s status as the biggest and most profitable bank in U.S. history. Here’s what the ...

Earlier this year, JPMorgan Chase was the victim of a massive data breach, but the attack might have been avoided if the bank had installed a “simple” security fix, The New York Times reveals.